

Valsartan

The Valsartan lawsuits claim that numerous batches of Valsartan have been found to be contaminated with the cancer-causing substances N-nitrosodimethylamine (NDMA), N-Nitrosodiethylamine (NDEA), and/or N-Methylnitrosobutyric acid (NMBA).

In February 2019, an MDL was established for Valsartan in federal court in New Jersey. Our law firm is serving as co-lead counsel for the MDL. As of October 2021, more than 950 lawsuits were pending in the MDL.

This website is a comprehensive list of the various announcements by the FDA regarding the Valsartan contamination issues. To read more, click <https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-angiotensin-ii-receptor-blocker-arb-recalls-valsartan-losartan>

Criteria

- Minimum 1 year usage 2015 or later
This one year of total usage must be before being diagnosed with cancer. (Usage before 2015 will not count as credit towards the necessary 1 year of total usage).
- Post 2017 diagnosis of one of the following cancers:
Stomach, Intestinal, Colorectal, Esophageal, Liver, Prostate (dx before age 65), Pancreatic, Leukemia, Non-Hodgkins Lymphoma or Multiple Myeloma



<https://www.levinlaw.com/valsartan-lawsuit>